Get the Stockscreener App
10.76
1.03%
0.11
Lyell Immunopharma Inc stock is traded at $10.76, with a volume of 21,762.
It is up +1.03% in the last 24 hours and up +4.67% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$10.65
Open:
$10.83
24h Volume:
21,762
Relative Volume:
0.16
Market Cap:
$206.71M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-13.62
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+1.70%
1M Performance:
+4.67%
6M Performance:
-23.22%
1Y Performance:
-62.90%
1-Day Range:
$10.50
$10.94
1-Week Range:
$10.49
$11.00
52-Week Range:
$7.65
$32.40
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
10.76 | 209.11M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Trendlines Converge — Decision Point for Lyell Immunopharma Inc.Trade Volume Summary & Free High Return Stock Watch Alerts - classian.co.kr
Lyell Immunopharma Inc. Could See a Relief Rally From SupportWeekly Market Report & Free Weekly Watchlist of Top Performers - thegnnews.com
Can Lyell Immunopharma Inc. reach all time highs this yearMarket Activity Report & Daily Entry Point Alerts - 선데이타임즈
What machine learning models say about Lyell Immunopharma Inc.Weekly Market Outlook & Daily Price Action Insights - Newser
Custom strategy builders for tracking Lyell Immunopharma Inc.2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Detecting price anomalies in Lyell Immunopharma Inc. with AIWeekly Trade Recap & High Conviction Investment Ideas - Newser
Is Lyell Immunopharma Inc. stock poised for growthPortfolio Gains Report & Long Hold Capital Preservation Plans - Newser
Real time scanner hits for Lyell Immunopharma Inc. explained2025 Performance Recap & Free Technical Confirmation Trade Alerts - Newser
What’s next for Lyell Immunopharma Inc. stock priceTrade Analysis Summary & Daily Profit Maximizing Tips - Newser
Relative strength of Lyell Immunopharma Inc. in sector analysisJuly 2025 Macro Moves & High Conviction Buy Zone Alerts - Newser
Applying big data sentiment scoring on Lyell Immunopharma Inc.2025 Institutional Moves & Verified Entry Point Signals - Newser
Will Lyell Immunopharma Inc. benefit from green energy policies2025 Stock Rankings & Consistent Income Trade Ideas - thegnnews.com
Will earnings trigger a reversal in Lyell Immunopharma Inc.Trend Reversal & Reliable Trade Execution Plans - Newser
Analyzing recovery setups for Lyell Immunopharma Inc. investorsTreasury Yields & Low Drawdown Trading Techniques - Newser
How to escape a deep drawdown in Lyell Immunopharma Inc.2025 Year in Review & Free High Accuracy Swing Entry Alerts - Newser
Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Wall Street Zen - Defense World
Sectors Driving Future Growth for Lyell Immunopharma Inc. Stock2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
How to use a screener to detect Lyell Immunopharma Inc. breakoutsTrade Volume Summary & Verified Technical Trade Signals - Newser
A | Can Lyell Immunopharma, Inc. Rally Enough to Break Even?2025 Market Sentiment & Long-Term Safe Return Strategies - newsyoung.net
Intraday pattern recognizer results for Lyell Immunopharma Inc.Earnings Risk Report & Detailed Earnings Play Strategies - Newser
What is the Moat Score of Lyell Immunopharma Inc.2025 Fundamental Recap & Fast Exit/Entry Strategy Plans - sundaytimes.kr
Lyell Immunopharma Secures $100M, Reports Promising LYL314 Results, and Cuts Net Loss in Q2 2025 - AInvest
Lyell Immunopharma Sells 3.75M Shares of Common Stock for Holders. - AInvest
Lyell Immunopharma Advances CAR T-Cell Therapies - TipRanks
Lyell Immunopharma COO Hill sells $1.9k in shares By Investing.com - Investing.com Nigeria
Lyell Immunopharma COO Hill sells $1.9k in shares - Investing.com India
Lyell Immunopharma CSO sells $2.8k in shares By Investing.com - Investing.com Nigeria
Lyell Immunopharma CFO Newton sells shares worth $2.7k By Investing.com - Investing.com Australia
Lyell Immunopharma CFO Newton sells shares worth $2.7k - Investing.com
Lyell Immunopharma CEO Seely sells shares worth $8k By Investing.com - Investing.com UK
Can you recover from losses in Lyell Immunopharma Inc.Gold Moves & Low Risk High Reward Trade Ideas - Newser
Lyell Immunopharma shares rise 1.04% intraday despite reporting a $42.7 million loss in Q2. - AInvest
Lyell Immunopharma: Q2 Earnings Snapshot - New Haven Register
Identifying reversal signals in Lyell Immunopharma Inc.July 2025 Chart Watch & AI Forecasted Entry and Exit Points - Newser
Will Lyell Immunopharma Inc. rebound enough to break evenMarket Performance Recap & Fast Gaining Stock Strategy Reports - Newser
Lyell Immunopharma 2025 Q2 Earnings Slight Improvement in Losses Amid Revenue Drop - AInvest
Forex Signals Brief for Aug 13: Cisco, Trump Media, Lyell Earnings in Focus - FXLeaders
Regression analysis insights on Lyell Immunopharma Inc. performanceReal-Time Setup Summary with ROI Focus - Newser
Lyell Immunopharma Reports Positive Clinical Data, $100mln Private Placement. - AInvest
Lyell Immunopharma's Share Sale and Its Implications for Market Confidence and Capital Flexibility - AInvest
Lyell Immunopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewswire
Lyell's New Lymphoma Treatment Outperforms Current CAR T-Cell Therapies with Superior Response Rates - Stock Titan
What technical models suggest about Lyell Immunopharma Inc.’s comebackChart-Based Entry Confirmation for Beginners - Newser
How Lyell Immunopharma Inc. stock performs during market volatilityHigh Yield Growth Opportunities - mustnews.co.kr
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyell Immunopharma Inc Stock (LYEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seely Lynn | President and CEO |
Aug 11 '25 |
Sale |
10.53 |
391 |
4,116 |
35,234 |
| Hill Stephen J. | Chief Operating Officer |
Aug 12 '25 |
Sale |
10.34 |
94 |
972 |
8,849 |
| Hill Stephen J. | Chief Operating Officer |
Aug 11 '25 |
Sale |
10.53 |
91 |
958 |
8,943 |
| Lee Gary K. | Chief Scientific Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,957 |
| Lee Gary K. | Chief Scientific Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
9,093 |
| Newton Charles W. | Chief Financial Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,759 |
| Newton Charles W. | Chief Financial Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
8,895 |
| BRAWLEY OTIS W | Director |
Mar 31 '25 |
Buy |
0.56 |
35,640 |
19,958 |
35,640 |
| Ramachandra Sumant | Director |
Mar 21 '25 |
Buy |
0.58 |
200,000 |
115,220 |
200,000 |
| Klausner Richard | Director |
Mar 14 '25 |
Buy |
0.60 |
158,000 |
94,942 |
843,365 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):